Daré Bioscience, Inc. (DARE)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
0.74 USD
0.00
(-0.501%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.72 -0.01 (-0.015%) ⇩ (Aug. 28, 2026, 7:58 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:32 a.m. EDT
The immediate outlook is severely bearish as the stock has collapsed from its recent highs, trading well below both the 50-day and 200-day moving averages, indicating significant downward momentum. While the company boasts a 'strong buy' analyst consensus and a lofty price target, these figures are disconnected from the harsh reality of the balance sheet, which shows negative book value, massive operating losses, and negative free cash flow. The business fundamentals are deteriorating rapidly, evidenced by four consecutive years of negative annual returns and a nearly 98% drop in value over the last nine years. With no dividend history and a history of reporting losses, there is no safety net for investors. The combination of a crumbling operational trajectory and a price that has already fallen precipitously suggests a high-risk speculative play rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.412045 |
| AutoETS | 0.415384 |
| AutoARIMA | 0.415384 |
| MSTL | 0.429024 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 24% |
| H-stat | 1179.94 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.220 |
| Excess Kurtosis | -1.14 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.097 |
| Market Cap | 14,240,763 |
| Forward P/E | -1.77 |
| Beta | 1.06 |
| Website | https://darebioscience.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6359606 |
| Address1 | 3,655 Nobel Drive |
| Address2 | Suite 260 |
| All Time High | 1,304.4 |
| All Time Low | 0.73 |
| Ask | 0.9436 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,516,390 |
| Average Daily Volume3 Month | 486,445 |
| Average Volume | 486,445 |
| Average Volume10Days | 1,516,390 |
| Beta | 1.055 |
| Bid | 0.5285 |
| Bid Size | 2 |
| Book Value | -0.037 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.735 |
| Current Ratio | 0.986 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.758 |
| Day Low | 0.72 |
| Display Name | Daré Bioscience |
| Dividend Date | 1,500,508,800 |
| Earnings Call Timestamp End | 1,786,653,000 |
| Earnings Call Timestamp Start | 1,786,653,000 |
| Earnings Timestamp | 1,786,651,200 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -8,978,829 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.6 |
| Enterprise To Revenue | 3.942 |
| Enterprise Value | 5,384,575 |
| Eps Current Year | -0.77333 |
| Eps Forward | -0.415 |
| Eps Trailing Twelve Months | -0.66 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.52358 |
| Fifty Day Average Change | -0.78857994 |
| Fifty Day Average Change Percent | -0.51758355 |
| Fifty Two Week Change Percent | -63.596058 |
| Fifty Two Week High | 3.78 |
| Fifty Two Week High Change | -3.045 |
| Fifty Two Week High Change Percent | -0.8055556 |
| Fifty Two Week Low | 0.72 |
| Fifty Two Week Low Change | 0.014999986 |
| Fifty Two Week Low Change Percent | 0.020833313 |
| Fifty Two Week Range | 0.72 - 3.78 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,397,136,600,000 |
| Float Shares | 14,041,573 |
| Forward Eps | -0.415 |
| Forward P E | -1.7710844 |
| Free Cashflow | -6,908,168 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 21 |
| Fullday Change | -0.00369996 |
| Fullday Change Percent | -0.500874 |
| Fullday Price | 0.7201 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 2.43908 |
| Gross Profits | 3,331,641 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12337 |
| Held Percent Institutions | 0.07972 |
| Implied Shares Outstanding | 19,375,189 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,719,792,000 |
| Last Split Factor | 1:12 |
| Long Business Summary | Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB2 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. It has a strategic collaboration with MyMenopauseRx. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California. |
| Long Name | Daré Bioscience, Inc. |
| Market | us_market |
| Market Cap | 14,240,763 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_423979060 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -10,987,146 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 14,358,952 |
| Number Of Analyst Opinions | 3 |
| Open | 0.758 |
| Operating Cashflow | -11,293,561 |
| Operating Margins | -15.82534 |
| Payout Ratio | 0.0 |
| Phone | 858 926 7655 |
| Post Market Change | -0.014900029 |
| Post Market Change Percent | -2.0272148 |
| Post Market Price | 0.7201 |
| Post Market Time | 1,787,961,504 |
| Previous Close | 0.7387 |
| Price Eps Current Year | -0.95043516 |
| Price Hint | 4 |
| Price To Book | -19.864864 |
| Price To Sales Trailing12 Months | 10.425621 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.749 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.00369996 |
| Regular Market Change Percent | -0.500874 |
| Regular Market Day High | 0.758 |
| Regular Market Day Low | 0.72 |
| Regular Market Day Range | 0.72 - 0.758 |
| Regular Market Open | 0.758 |
| Regular Market Previous Close | 0.7387 |
| Regular Market Price | 0.735 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 354,162 |
| Return On Assets | -0.39286998 |
| Revenue Per Share | 0.097 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 19,375,189 |
| Shares Percent Shares Out | 0.0763 |
| Shares Short | 1,166,572 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 601,255 |
| Short Name | Dare Bioscience, Inc. |
| Short Percent Of Float | 0.076799996 |
| Short Ratio | 1.51 |
| Source Interval | 15 |
| State | CA |
| Symbol | DARE |
| Target High Price | 12.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 8.33333 |
| Target Median Price | 8.0 |
| Total Cash | 12,617,594 |
| Total Cash Per Share | 0.825 |
| Total Debt | 6,763,626 |
| Total Revenue | 1,365,939 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.66 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.852245 |
| Two Hundred Day Average Change | -1.117245 |
| Two Hundred Day Average Change Percent | -0.6031842 |
| Type Disp | Equity |
| Volume | 354,162 |
| Website | https://darebioscience.com |
| Zip | 92,122 |